Pembrolizumab,389,390 and nivolumab,391 are widely used PD-1 inhibitors, while atezolizumab, durvalumab, and avelumab specifically target PD-L1.57,392 These ICIs are approved for treating various cancers. The gene discussed is PDCD1; the disease is cancer.